RT Journal Article SR Electronic T1 Feasibility and patient satisfaction with transnasal diagnostic EUS-b under conscious sedation JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP 2855 DO 10.1183/13993003.congress-2020.2855 VO 56 IS suppl 64 A1 Gonçalo António Cintrão Samouco A1 Michele De Santis A1 Paulo Matos A1 Lourdes Barradas YR 2020 UL http://erj.ersjournals.com/content/56/suppl_64/2855.abstract AB Introduction: EUS-b is a safe procedure, complementary of EBUS for mediastinal staging of lung cancer. By reaching otherwise inaccessible locations, it may be useful as a diagnostic exam. There are no available data on the ideal route of insertion for the procedure.Aim: Evaluate patient comfort, safety and the diagnostic yield of EUS-b via the nasal route.Methods: Prospective study enrolling patients with suspected malignant or benign disease undergoing EUS-b at an oncological center from November 2019 to January 2020. Nasal insertion under midazolam was attempted in all patients, who completed a questionnaire at discharge. Data regarding the procedure, histological analysis, patient comfort and satisfaction (on a 5-point scale) were collected.Results: 39 patients underwent diagnostic EUS-b, mostly male (64,1%) with mean age of 64,8±14,4 years. In 7 patients (17,9%) nasal insertion failed and the procedure was completed via the oral route. The mean dose of midazolam administered was 3,4±0,7mg and the mean procedure duration was 15,9±5,3min. In most patients (84,8%) only one site was sampled. Most sampled locations were station 7 (53,3%) and lung lesions (26,7%). No serious complications were reported.Perceived patient comfort during the procedure was 4,1/5 and patients’ reported comfort was 4,0/5. Overall satisfaction was 4,3/5. All patients declared willingness to repeat the procedure if necessary.Adequate specimens were obtained in 83,3% and diagnostic yield was 76,7%.Conclusion: Transnasal EUS-b under conscious sedation is feasible and well tolerated when nasal anatomy is compatible. Based on these results, a prospective multi-center trial comparing insertion routes is currently underway.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2855.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).